-
2
-
-
84859435388
-
Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients
-
Hautmann R.E., de Petriconi R.C., Pfeiffer C., Volkmer B.G. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012, 61:1039-1047.
-
(2012)
Eur Urol
, vol.61
, pp. 1039-1047
-
-
Hautmann, R.E.1
de Petriconi, R.C.2
Pfeiffer, C.3
Volkmer, B.G.4
-
3
-
-
33751057732
-
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium
-
Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006, 176:2414-2422.
-
(2006)
J Urol
, vol.176
, pp. 2414-2422
-
-
Shariat, S.F.1
Karakiewicz, P.I.2
Palapattu, G.S.3
-
4
-
-
84865287448
-
Current therapeutic strategies for invasive and metastatic bladder cancer
-
Vishnu P., Mathew J., Tan W.W. Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther 2011, 4:97-113.
-
(2011)
Onco Targets Ther
, vol.4
, pp. 97-113
-
-
Vishnu, P.1
Mathew, J.2
Tan, W.W.3
-
5
-
-
84859778293
-
MTOR signaling in growth control and disease
-
Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
-
(2012)
Cell
, vol.149
, pp. 274-293
-
-
Laplante, M.1
Sabatini, D.M.2
-
6
-
-
84861515834
-
Targeting PI3 kinase/AKT/mTOR signaling in cancer
-
Sheppard K., Kinross K.M., Solomon B., Pearson R.B., Phillips W.A. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 2012, 17:69-95.
-
(2012)
Crit Rev Oncog
, vol.17
, pp. 69-95
-
-
Sheppard, K.1
Kinross, K.M.2
Solomon, B.3
Pearson, R.B.4
Phillips, W.A.5
-
7
-
-
79957983577
-
Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs
-
Markman B., Dienstmann R., Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010, 1:530-543.
-
(2010)
Oncotarget
, vol.1
, pp. 530-543
-
-
Markman, B.1
Dienstmann, R.2
Tabernero, J.3
-
8
-
-
84874048152
-
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications
-
Tickoo S.K., Milowsky M.I., Dhar N., et al. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int 2011, 110:1237-1248.
-
(2011)
BJU Int
, vol.110
, pp. 1237-1248
-
-
Tickoo, S.K.1
Milowsky, M.I.2
Dhar, N.3
-
9
-
-
63049094489
-
Inactivation of p53 and PTEN promotes invasive bladder cancer
-
Puzio-Kuter A.M., Castillo-Martin M., Kinkade C.W., et al. Inactivation of p53 and PTEN promotes invasive bladder cancer. Genes Dev 2009, 23:675-680.
-
(2009)
Genes Dev
, vol.23
, pp. 675-680
-
-
Puzio-Kuter, A.M.1
Castillo-Martin, M.2
Kinkade, C.W.3
-
10
-
-
81055144867
-
S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer
-
Nawroth R., Stellwagen F., Schulz W.A., et al. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One 2011, 6:e27509.
-
(2011)
PLoS One
, vol.6
-
-
Nawroth, R.1
Stellwagen, F.2
Schulz, W.A.3
-
11
-
-
84890791290
-
Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: effect on prognostic outcomes following radical nephrectomy
-
Nishikawa M., Miyake H., Harada K., Fujisawa M. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: effect on prognostic outcomes following radical nephrectomy. Urol Oncol 2014, 32. 49.(e15-21).
-
(2014)
Urol Oncol
, vol.32
, pp. 49+e15-e21
-
-
Nishikawa, M.1
Miyake, H.2
Harada, K.3
Fujisawa, M.4
-
12
-
-
0037441652
-
Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy
-
Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003, 21:690-696.
-
(2003)
J Clin Oncol
, vol.21
, pp. 690-696
-
-
Madersbacher, S.1
Hochreiter, W.2
Burkhard, F.3
-
13
-
-
78650990540
-
The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases
-
Abou Youssif T., Fahmy M.A., Koumakpayi I.H., et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 2011, 117:290-300.
-
(2011)
Cancer
, vol.117
, pp. 290-300
-
-
Abou Youssif, T.1
Fahmy, M.A.2
Koumakpayi, I.H.3
-
14
-
-
6044223545
-
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers
-
Zhou X., Tan M., Stone Hawthorne V., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10:6779-6788.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 6779-6788
-
-
Zhou, X.1
Tan, M.2
Stone Hawthorne, V.3
-
15
-
-
70049113978
-
Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics
-
Dai B., Kong Y.Y., Ye D.W., Ma C.G., Zhou X., Yao X.D. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 2012, 104:1009-1016.
-
(2012)
BJU Int
, vol.104
, pp. 1009-1016
-
-
Dai, B.1
Kong, Y.Y.2
Ye, D.W.3
Ma, C.G.4
Zhou, X.5
Yao, X.D.6
-
16
-
-
84896691995
-
The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma
-
Lee Y.J., Hah Y.J., Kang Y.N., et al. The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma. PLoS One 2013, 8:e81540.
-
(2013)
PLoS One
, vol.8
-
-
Lee, Y.J.1
Hah, Y.J.2
Kang, Y.N.3
-
17
-
-
0035675829
-
Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model
-
Miyake H., Hara I., Kamidono S., Gleave M.E. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001, 7:4245-4252.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 4245-4252
-
-
Miyake, H.1
Hara, I.2
Kamidono, S.3
Gleave, M.E.4
-
18
-
-
0028861211
-
P53 Immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder
-
Serth J., Kuczyk M.A., Bokemeyer C., et al. p53 Immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995, 71:201-205.
-
(1995)
Br J Cancer
, vol.71
, pp. 201-205
-
-
Serth, J.1
Kuczyk, M.A.2
Bokemeyer, C.3
-
19
-
-
84863442079
-
Current status of molecular markers for prognostication and outcome in invasive bladder cancer
-
Gakis G., Schwentner C., Todenhöfer T., Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int 2012, 110:233-237.
-
(2012)
BJU Int
, vol.110
, pp. 233-237
-
-
Gakis, G.1
Schwentner, C.2
Todenhöfer, T.3
Stenzl, A.4
-
20
-
-
33750089285
-
Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer
-
Castellvi J., Garcia A., Rojo F., et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006, 107:1801-1811.
-
(2006)
Cancer
, vol.107
, pp. 1801-1811
-
-
Castellvi, J.1
Garcia, A.2
Rojo, F.3
-
21
-
-
32944457518
-
MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
-
(2006)
Cancer Res
, vol.66
, pp. 1500-1508
-
-
O'Reilly, K.E.1
Rojo, F.2
She, Q.B.3
-
22
-
-
84863393353
-
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
-
Gupta M., Hendrickson A.E., Yun S.S., et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 2012, 119:476-487.
-
(2012)
Blood
, vol.119
, pp. 476-487
-
-
Gupta, M.1
Hendrickson, A.E.2
Yun, S.S.3
-
23
-
-
84887022988
-
Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2
-
Harada K., Miyake H., Kumano M., et al. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Br J Cancer 2013, 109:2389-2395.
-
(2013)
Br J Cancer
, vol.109
, pp. 2389-2395
-
-
Harada, K.1
Miyake, H.2
Kumano, M.3
-
24
-
-
84897033468
-
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
-
Ducker G.S., Atreya C.E., Simko J.P., et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2014, 33:1590-1600.
-
(2014)
Oncogene
, vol.33
, pp. 1590-1600
-
-
Ducker, G.S.1
Atreya, C.E.2
Simko, J.P.3
-
25
-
-
15044340650
-
Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin factor 4E-binding proteins
-
Wang X., Beugnet A., Murakami M., et al. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin factor 4E-binding proteins. Mol Cell Biol 2005, 25:2558-2572.
-
(2005)
Mol Cell Biol
, vol.25
, pp. 2558-2572
-
-
Wang, X.1
Beugnet, A.2
Murakami, M.3
-
26
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 31:2271-2281.
-
(2007)
N Engl J Med
, vol.31
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
27
-
-
34548028705
-
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications
-
Armengol G., Rojo F., Castellví J., et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007, 67:7551-7555.
-
(2007)
Cancer Res
, vol.67
, pp. 7551-7555
-
-
Armengol, G.1
Rojo, F.2
Castellví, J.3
-
28
-
-
34848901974
-
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity
-
Graff J.R., Konicek B.W., Vincent T.M., et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007, 117:2638-2648.
-
(2007)
J Clin Invest
, vol.117
, pp. 2638-2648
-
-
Graff, J.R.1
Konicek, B.W.2
Vincent, T.M.3
-
29
-
-
49749125291
-
Targeting the eIF4F translation initiation complex for cancer therapy
-
Konicek B.W., Dumstorf C.A., Graff J.R. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 2008, 7:2466-2471.
-
(2008)
Cell Cycle
, vol.7
, pp. 2466-2471
-
-
Konicek, B.W.1
Dumstorf, C.A.2
Graff, J.R.3
-
30
-
-
80054114844
-
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
-
Hong D.S., Kurzrock R., Oh Y., et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 2011, 17:6582-6591.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6582-6591
-
-
Hong, D.S.1
Kurzrock, R.2
Oh, Y.3
|